Evan Loh climbs the lad­der to be­come CEO at Paratek Phar­ma­ceu­ti­cals; Co­di­ak's Doug Williams takes chair­man's role at AC Im­mune

Evan Loh Paratek

De­ter­mined to be the good sto­ry that the an­tibi­otics field so des­per­ate­ly needs, Paratek Phar­ma­ceu­ti­cals $PRTK is reshuf­fling its top-lev­el man­age­ment to han­dle a grow­ing com­mer­cial op­er­a­tion. Evan Loh has be­come CEO af­ter climb­ing the lad­der over the past sev­en years (from CMO to pres­i­dent and COO) while Michael Bigham claims the new­ly cre­at­ed po­si­tion of ex­ec­u­tive chair­man. They will over­see life cy­cle ex­pan­sion ini­tia­tives for Nuzyra with chief com­mer­cial of­fi­cer Adam Woodrow, who’s been pro­mot­ed to pres­i­dent. Mean­while, Randy Bren­ner will take up ad­di­tion­al re­spon­si­bil­i­ties in med­ical af­fairs af­ter lead­ing the reg­u­la­to­ry ef­forts for Paratek.

Doug Williams, the CEO at Co­di­ak, is tak­ing the chair­man’s po­si­tion at Swiss biotech AC Im­mune, which has spent years pur­su­ing new ther­a­pies for Alzheimer’s dis­ease. Williams was a top ex­ec at Bio­gen with George Scan­gos’ crew be­fore he left well ahead of the big biotech’s cur­rent tra­vails with Alzheimer’s.

Yaky Yanay Linkedin

→ Is­raeli biotech Pluris­tem has of­fi­cial­ly phased out its co-CEO struc­ture, in­stalling Yaky Yanay as the sole chief and pres­i­dent. Za­mi Aber­man will be­come ex­ec­u­tive chair­man, with a man­date to shape cor­po­rate de­vel­op­ment and busi­ness strat­e­gy. The tran­si­tion comes as the com­pa­ny wraps up its Phase III and be­gins pon­der­ing com­mer­cial­iza­tion of its pla­cen­ta-based cell ther­a­pies, which treat crit­i­cal limb is­chemia and hip frac­ture among oth­er dis­eases. 

Mar­garet Olinger Linkedin

Amy­lyx Phar­ma­ceu­ti­cals has laid rel­a­tive­ly low since break­ing out six years ago with sup­port from the late Hen­ri Ter­meer. But the young founders are now con­fi­dent enough in their Phase II work in amy­otroph­ic lat­er­al scle­ro­sis and Alzheimer’s dis­ease to re­cruit some sea­soned ex­ecs to their team. Patrick Yerami­an, who’s been con­sult­ing with the Cam­bridge, MA-based com­pa­ny, joins as the full-time CMO; Alex­ion vet Mar­garet Olinger is the new chief com­mer­cial of­fi­cer; and Tom Holmes jumps from Bio­gen to head the sup­ply chain.

→ Mov­ing fast and plan­ning way ahead have been cen­tral tenets at Ar­cus Bio­sciences, and it is once again show­ing in their ap­point­ment of a chief com­mer­cial of­fi­cer long be­fore en­ter­ing late-stage stud­ies. Er­ic Hoe­fer, an I/O vet who’s cred­it­ed for help­ing launch Imfinzi at As­traZeneca, is tasked with ad­vis­ing the team on iden­ti­fy­ing key pa­tient pop­u­la­tions, mar­ket op­por­tu­ni­ties and po­ten­tial ap­proach­es to ac­cel­er­ate de­vel­op­ment. Ar­cus’ most ad­vanced pro­gram com­bines AB928, a dual adeno­sine re­cep­tor an­tag­o­nist, and AB122, a cheap PD-1 drug li­censed from WuXi.

Mor­phoSys has re­cruit­ed ex-Syn­tim­mune chief Jean-Paul Kress to take the helm as Si­mon Mo­roney makes his planned ex­it from the C-suite. Mo­roney steps down at the be­gin­ning of Sep­tem­ber. Kress helped arrange the sale of Syn­tim­mune to Alex­ion.

Er­ic Hoe­fer Twit­ter

In the fi­nal lead-up to its all-im­por­tant BLA sub­mis­sion slat­ed for Q3, DBV Tech­nolo­gies has raid­ed Mil­len­do Ther­a­peu­tics for a new CMO. Phar­is Mo­hideen will work close­ly with CSO Hugh Samp­son, who’s been dou­bling in the med­ical role ad in­ter­im. Aside from their peanut al­ler­gy prod­uct, the French biotech is al­so de­vel­op­ing a non-in­va­sive way to de­liv­er bi­o­log­i­cal­ly ac­tive com­pounds to the im­mune sys­tem through the skin.

→ Long­time in­vest­ment banker Pe­ter Col­lum is mak­ing the leap to the in­dus­try as CFO and CBO at Pharnext, a French com­pa­ny he’s got­ten to know in the past five years. Its pleother­a­py plat­form iden­ti­fies the ide­al com­bi­na­tion of avail­able med­i­cines to fight tar­gets un­der­ly­ing, of­ten rare, dis­ease. 

Qrons has tapped John Bon­figlio to spear­head IND ac­tiv­i­ties sur­round­ing its hy­dro­gel for trau­mat­ic brain in­juries. As COO, Bon­figlio will op­er­ate from the biotech’s New York head­quar­ters and co­or­di­nate with the sci­en­tif­ic team in Is­rael. Be­fore start­ing his own con­sult­ing group, he helmed sev­er­al drug de­vel­op­ment com­pa­nies in­clud­ing TapIm­mune, Or­a­gen­ics and Pere­grine.

Paul Fos­ter Xen­cor

→ CMO and se­nior vice pres­i­dent of Xen­cor — a com­pa­ny fo­cused on de­vel­op­ing en­gi­neered mon­o­clon­al an­ti­bod­ies for the treat­ment of var­i­ous dis­eases and ill­ness­es — Paul Fos­ter will be step­ping out the door and in­to re­tire­ment ef­fec­tive Oc­to­ber 31, 2019, af­ter a decade of ser­vice. While at the com­pa­ny, Fos­ter ad­vanced a di­verse pipeline of XmAb bis­pe­cif­ic an­ti­bod­ies in­to ear­ly-stage clin­i­cal de­vel­op­ment. The com­pa­ny has ini­ti­at­ed a search for a suc­ces­sor. 

→ Mel­bourne, Aus­tralia-based Propanc Bio­phar­ma wel­comed Car­lo Campi­ciano to the ranks as CFO of the com­pa­ny. For over a decade, Campi­ciano has served as an ex­ter­nal ad­vi­sor for the com­pa­ny while al­so serv­ing as CFO of a start­up — which grew from an an­nu­al turnover of $2 mil­lion to $40 mil­lion, run­ning a pri­vate ac­count­ing prac­tice for over 30 years and serv­ing as a lec­tur­er for 12 years at Swin­burne Uni­ver­si­ty.

→ Ahead of its Phase III de­vel­op­ment of en­sifen­trine, Verona Phar­ma — a com­pa­ny fo­cused on res­pi­ra­to­ry dis­eases — added Ni­na Church and Nan­cy Her­je to the fold. GSK vet Church will serve as ex­ec­u­tive di­rec­tor of glob­al clin­i­cal de­vel­op­ment and Her­je will join as se­nior di­rec­tor of clin­i­cal op­er­a­tions. Dur­ing her 25 years at GSK, Church was in­volved in the de­vel­op­ment of Ad­vair, Anoro, Flovent, Serevent and Ven­tolin. She joins Verona from Par­i­on Sci­ences where she served as ex­ec­u­tive di­rec­tor, clin­i­cal op­er­a­tions. Pri­or to join­ing Verona, Her­je was a se­nior clin­i­cal sci­en­tist at Ex­e­cuPharm. She has had pre­vi­ous stints at Chimerix, Ae­ro­crine, In­spire and GSK

Nan­cy Her­je Linkedin

Abeona Ther­a­peu­tics — a com­pa­ny de­vel­op­ing cell and gene ther­a­pies — has strength­ened its lead­er­ship board with the ad­di­tion of Vic­tor Paulus as se­nior vice pres­i­dent of reg­u­la­to­ry af­fairs and Jodie Gillon as vice pres­i­dent of pa­tient ad­vo­ca­cy and clin­i­cal af­fairs. 

Pri­or to join­ing Abeona, Paulus served as vice pres­i­dent and glob­al head of reg­u­la­to­ry af­fairs at Hookipa Phar­ma. He’s al­so served at No­var­tis com­pa­ny, Ad­vanced Ac­cel­er­a­tor Ap­pli­ca­tions, where he se­cured or­phan des­ig­na­tions and prod­uct ap­provals for Gal­li­um Ga68 dotatate and Lutetium Lu177 dotatate and has held stints at GSK and Dr. Red­dy’s

Jodie Gillon Linkedin

Gillon has had over a decade of ex­pe­ri­ence at Pfiz­er — where she was the glob­al med­ical lead for pa­tient en­gage­ment. She’s al­so pre­vi­ous­ly served at Achillion Phar­ma­ceu­ti­cals, As­traZeneca, No­var­tis and Orid­ion

Im­pel Neu­roPhar­ma — fo­cused on ther­a­pies to treat pa­tients with cen­tral ner­vous sys­tem dis­or­ders, such as INP104 (POD-DHE) for acute mi­graine headaches — has tapped John Lea­man as CFO. Most re­cent­ly, Lea­man served at Se­lec­ta Bio­sciences in the same role and has served in oth­er lead­er­ship po­si­tions at Med­gen­ics, Shire and De­von Park Bioven­tures.

Vi­a­Cyte — a stem cell play­er who fu­eled up with $105 mil­lion for its next big at­tack on di­a­betes last No­vem­ber — has en­list­ed San­dra E. Poole to its board of di­rec­tors. Most re­cent­ly, Poole served as the COO of genome edit­ing com­pa­ny, Log­icBio Ther­a­peu­tics. Poole’s has held stints at Im­muno­Gen and Gen­zyme (now Sanofi Gen­zyme). Poole cur­rent­ly serves on the board of di­rec­tors of Retrophin and the su­per­vi­so­ry board of Val­ne­va, SE — a France-based vac­cine com­pa­ny. 

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,400+ biopharma pros reading Endpoints daily — and it's free.

The Advance Clinical leadership team: CEO Yvonne Lungershausen, Sandrien Louwaars - Director Business Development Operations, Gabriel Kremmidiotis - Chief Scientific Officer, Ben Edwards - Chief Strategy Officer

How Aus­tralia De­liv­ers Rapid Start-up and 43.5% Re­bate for Ear­ly Phase On­col­o­gy Tri­als

About Avance Clinical

Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services to the local and international drug development industry for 20 years. They specialise in working with biotech companies to execute Phase 1 and Phase 2 clinical trials to deliver high-quality outcomes fit for global regulatory standards.

As oncology sponsors look internationally to speed-up trials after unprecedented COVID-19 suspensions and delays, Australia, which has led the world in minimizing the pandemic’s impact, stands out as an attractive destination for early phase trials. This in combination with the streamlined regulatory system and the financial benefits including a very favourable exchange rate and the R & D cash rebate makes Australia the perfect location for accelerating biotech clinical programs.

Dan O'Day, Gilead CEO (Andrew Harnik, AP Images)

UP­DAT­ED: Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

Gilead CEO Dan O’Day has brokered his way to a PD-1 and lined up a front row seat in the TIGIT arena, inking a deal worth close to $2 billion to align the big biotech closely with Terry Rosen’s Arcus. And $375 million of that comes upfront, with cash for the buy-in plus equity, along with $400 million for R&D and $1.22 billion in reserve to cover opt-in payments and milestones..

Hotly rumored for weeks, the 2 players have formalized a 10-year alliance that starts with rights to the PD-1, zimberelimab. O’Day also has first dibs on TIGIT and 2 other leading programs, agreeing to an opt-in fee ranging from $200 million to $275 million on each. There’s $500 million in potential TIGIT milestones on US regulatory events — likely capped by an approval — if Gilead partners on it and the stars align on the data. And there’s another $150 million opt-in payments for the rest of the Arcus pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,400+ biopharma pros reading Endpoints daily — and it's free.

Roger Perlmutter, Merck R&D chief (YouTube)

UP­DAT­ED: Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

Merck execs are making a triple play in a sudden leap into the R&D campaign against Covid-19. And they have more BARDA cash backing them up on the move.

Tuesday morning the pharma giant simultaneously announced plans to buy an Austrian biotech that has been working on a preclinical vaccine candidate, added a collaboration on another vaccine with the nonprofit IAVI and inked a deal with Ridgeback Biotherapeutics on an early-stage antiviral.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,400+ biopharma pros reading Endpoints daily — and it's free.

Bryan Roberts, Venrock

Ven­rock sur­vey shows grow­ing recog­ni­tion of coro­n­avirus toll, wan­ing con­fi­dence in ar­rival of vac­cines and treat­ments

When Venrock partner Bryan Roberts went to check the results from their annual survey of healthcare leaders, what he found was an imprint of the pandemic’s slow arrival in America.

The venture firm had sent their form out to hundreds of insurance and health tech executives, investors, officials and academics on February 24 and gave them two weeks to fill it out. No Americans had died at that point but the coronavirus had become enough of a global crisis that they included two questions about the virus, including “Total U.S. deaths in 2020 from the novel coronavirus will be:”.

Covid-19 roundup: Buoyed by soar­ing shares, No­vavax inks a $167M deal to buy Covid-19 vac­cine-mak­ing fa­cil­i­ty; France cools on hy­drox­y­chloro­quine

The pandemic has offered the best news Novavax has had in years. Its stock price is trading at 7x the pre-panic levels with a Covid-19 vaccine in the mix, as investors buy anything that moves in that field, and they’re flush to carve out their own pathway on the manufacturing front.

Wednesday morning Novavax reported that they are spending $167 million on the Czech-based Praha Vaccines, bagging a manufacturing facility along the way.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,400+ biopharma pros reading Endpoints daily — and it's free.

Bris­tol My­ers Squibb fi­nal­ly gets in the front­line NSCLC game dom­i­nat­ed by Mer­ck, adding a sec­ond Op­di­vo/Yer­voy-based op­tion

Bristol Myers Squibb may be trailing Merck and Roche in the checkpoint race to treat frontline cases of non-small cell lung cancer, but as it does, it makes sure to bring its best feet forward.

Just days after scoring a landmark NSCLC approval for Opdivo and Yervoy alone for PD-L1 positive patients, the company said the FDA has also OK’d using the two agents with a limited course of chemo regardless of the biomarker status.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,400+ biopharma pros reading Endpoints daily — and it's free.

Fabrice Chouraqui, Cellarity CEO-partner (LinkedIn)

Drug de­vel­op­er, Big Phar­ma com­mer­cial ex­ec, now an up­start biotech chief — Fab­rice Chouraqui is ready to try some­thing new as a ‘CEO-part­ner’ at Flag­ship

Fabrice Chouraqui’s career has taken some big twists along his life journey. He got his PharmD at Université Paris Descartes and jumped into the drug development game for a bit. Then he took a sharp turn and went back to school to get his MBA at Insead before returning to pharma on the commercial side.

Twenty years later, after steadily rising through the ranks and journeying the globe to nab a top job as president of US pharma for the Basel-based Novartis, Chouraqui exited in another career switch. And now he’s headed into a hybrid position as a CEO-partner at Flagship, where he’ll take a shot at leading Cellarity — one of the VC’s latest paradigm-changing companies of the groundbreaking model that aspires to deliver a new platform to the world of drug R&D.

via Shutterstock

Ex-biotech chief pleads guilty in col­lege ad­mis­sions scan­dal, faces a 10-month prison stretch in plea deal

The ex-CEO of Harmony Biosciences — as well as former board member for Biohaven — has agreed to plead guilty to two counts of mail fraud after getting caught up in the college admissions scandal.

Charged with paying Georgetown University’s former tennis coach more than $50,000 to get his daughter admitted to the university as a new recruit for the team, Bob Repella took the plea deal, which comes with a recommended sentence of 10 months in prison, with a year of supervised release and a $40,000 fine.